Technical Analysis for OTLK - Outlook Therapeutics, Inc.

Grade Last Price % Change Price Change
F 7.79 -5.52% -0.46
OTLK closed down 5.52 percent on Monday, March 18, 2024, on 2.56 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
Calm After Storm Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Slingshot Bearish Bearish Swing Setup -5.52%
Bullish Engulfing Bullish -5.52%
Crossed Above 20 DMA Bullish -5.52%
Crossed Above 50 DMA Bullish -5.52%
New Uptrend Bullish -5.52%

   Recent Intraday Alerts

Alert Time
Possible Inside Day about 17 hours ago
20 DMA Support about 20 hours ago
50 DMA Support about 20 hours ago
Up 2% about 20 hours ago
Up 1% about 20 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Outlook Therapeutics, Inc. Description

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was founded in 2010 and is headquartered in Cranbury, New Jersey.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Life Sciences Antibodies Cancer Treatment Monoclonal Antibodies Monoclonal Antibody Ophthalmic Macular Degeneration Specialty Drugs Retina Wet Age Related Macular Degeneration Age Related Macular Degeneration

Is OTLK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 40.6
52 Week Low 4.004
Average Volume 161,869
200-Day Moving Average 15.35
50-Day Moving Average 8.02
20-Day Moving Average 8.07
10-Day Moving Average 7.52
Average True Range 1.12
RSI (14) 66.10
ADX 28.54
+DI 48.53
-DI 14.09
Chandelier Exit (Long, 3 ATRs) 7.36
Chandelier Exit (Short, 3 ATRs) 8.40
Upper Bollinger Bands 9.69
Lower Bollinger Band 6.45
Percent B (%b) 0.41
BandWidth 40.18
MACD Line -0.29
MACD Signal Line -0.19
MACD Histogram -0.0974
Fundamentals Value
Market Cap 2.03 Billion
Num Shares 260 Million
EPS -0.24
Price-to-Earnings (P/E) Ratio -32.44
Price-to-Sales 13.27
Price-to-Book 10.19
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.45
Resistance 3 (R3) 9.48 8.95 9.17
Resistance 2 (R2) 8.95 8.52 8.94 9.08
Resistance 1 (R1) 8.37 8.26 8.10 8.34 8.99
Pivot Point 7.84 7.84 7.71 7.83 7.84
Support 1 (S1) 7.26 7.41 6.99 7.23 6.58
Support 2 (S2) 6.73 7.15 6.72 6.49
Support 3 (S3) 6.15 6.73 6.40
Support 4 (S4) 6.12